

VPA10420/003/001

**Novocillin LC 1000 mg intramammary suspension for lactating cows**

Variation	Summary	Date
Vet - F.II.f.1 c)	VRA-R - Vet - F.II.f.1 c) - c) Change in storage conditions of the finished product or the diluted/reconstituted product - F.II.f.1 c) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Change in storage conditions of the finished product or the diluted/reconstituted product	02/07/24
Vet - F.II.f.1 z)	VRA-R - Vet - F.II.f.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.f.1 z) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	02/07/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	24/05/23
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	13/03/23
Vet - F.II.b.1 d)	VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterinary medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products - F.II.b.1 d) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterinary medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products	04/08/22
B.II.e.5.a.2	IB - B.II.e.5.a.2 - 2. Change outside the range of the currently approved pack sizes - B.II.e.5.a.2 - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	28/02/22
B.II.b.1.a	IAin - B.II.b.1.a - a) Secondary packaging site - B.II.b.1.a - QUALITY CHANGES - FINISHED PRODUCT - Manufacture	28/02/22

	- Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Secondary packaging site	
B.II.b.2.c.2	IAin - B.II.b.2.c.2 - 2. Including batch control/testing - B.II.b.2.c.2 - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change to importer, batch release arrangements and quality control testing of the finished product - Replacement or addition of a manufacturer responsible for importation and/or batch release - Including batch control/testing	28/02/22